tradingkey.logo
Search
Markets
Watchlist
News
Analysis
Tools
Stock Screener
English
繁体中文
ไทย
Tiếng việt
简体中文
Español
Português
Deutsch
한국어
日本語
tradingkey.logo
Search

Axsome Therapeutics Inc

AXSM
Add to Watchlist
132.370USD
+2.570+1.98%
Close 11-05 16:00（ET）
6.93BMarket Cap
LossP/E TTM

Axsome Therapeutics Inc

132.370
+2.570+1.98%
Overview
News&Analysis
Financials
Stock Score
Technical
Forecast
Ownership
Dividends
Profile
Discussions
Financial SummaryIncome StatementBalance SheetCash Flow StatementRevenueEarningsCompany ValuationRisk Assessment

Overview

News&Analysis

Financials

Stock Score

Technical

Forecast

Ownership

Dividends

Profile

Discussions

Financial SummaryIncome StatementBalance SheetCash Flow StatementRevenueEarningsCompany ValuationRisk Assessment

AXSM Financials

See Axsome Therapeutics Inc's financials through an all-in-one data dashboard designed for smart investors. This provides you with financial analysis by organizing complex financial statements into customizable views. Access the latest annual financial report or break down performance quarter-by-quarter using the income statement, balance sheet, and cash flow statement. With real-time financial indicators at your fingertips, monitoring a company's market health over time has never been easier.
Key Financial Ratios
Market Cap
6.93B
Dividend TTM
0.00
P/E TTM
-35.52
EPS TTM
-3.73
Revenue
638.50M
Net Profit
-287.22M
ROE
-349.38%
ROA
-28.74%
Axsome Therapeutics Inc Earnings Date
Latest Release
Nov 2, 2026
EPS / Forecast
-0.25/-0.59
Revenue / Forecast
259.69M/249.93M

Financial Statement Highlights

Quarterly
Quarterly+Annual
Quarterly
Annual
FY2026Q3
FY2026Q2
FY2026Q1
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021Q4
Financial Indicators
EPS
74.00%-0.25
-2.10%-0.99
-3.69%-1.26
63.45%-0.56
29.64%-0.94
41.82%-0.97
15.71%-1.22
25.93%-1.54
-1.66%-1.34
-8.43%-1.67
-459.58%-1.44
-47.91%-2.08
---1.32
---1.54
---0.26
---1.41
---3.17
----
----
----
Revenue
51.87%259.69M
45.54%218.38M
57.42%191.20M
65.03%196.00M
63.22%170.99M
72.13%150.04M
61.95%121.46M
66.04%118.77M
81.27%104.76M
86.65%87.17M
-20.70%75.00M
193.50%71.53M
243.08%57.79M
429.49%46.70M
--94.58M
--24.37M
--16.85M
--8.82M
----
----
Net Profit
72.73%-12.88M
-6.96%-51.31M
-8.63%-64.54M
61.88%-28.56M
26.89%-47.23M
39.54%-47.97M
13.08%-59.41M
24.06%-74.91M
-3.86%-64.60M
-18.13%-79.34M
-509.35%-68.36M
-61.09%-98.65M
-38.77%-62.20M
-62.10%-67.17M
71.69%-11.22M
-80.24%-61.24M
-28.50%-44.82M
-28.36%-41.44M
-35.45%-39.63M
-16.50%-33.98M
Net Margin
82.05%-4.96%
26.51%-23.50%
30.99%-33.76%
76.90%-14.57%
55.21%-27.62%
64.88%-31.97%
46.33%-48.91%
54.27%-63.08%
42.70%-61.67%
36.71%-91.03%
-668.41%-91.14%
45.11%-137.92%
---107.62%
---143.83%
---11.86%
---251.28%
---490.52%
----
----
----
Gross Margin
0.47%92.53%
3.43%93.06%
0.92%91.48%
3.45%92.89%
1.86%92.09%
1.17%89.98%
1.30%90.65%
2.69%89.79%
5.23%90.41%
2.52%88.93%
-0.96%89.49%
4.09%87.44%
--85.92%
--86.75%
--90.35%
--84.01%
--78.81%
----
----
----
Debt to assets ratio
-15.73%24.53%
-12.01%26.59%
-11.91%27.59%
-13.39%28.20%
-11.29%29.11%
-9.74%30.22%
-5.58%31.32%
7.54%32.55%
11.11%32.81%
15.81%33.48%
-12.55%33.17%
6.46%30.27%
--29.53%
--28.91%
--37.93%
--28.44%
--27.71%
----
----
----
Income Statement
Revenue
51.87%259.69M
45.54%218.38M
57.42%191.20M
65.03%196.00M
63.22%170.99M
72.13%150.04M
61.95%121.46M
66.04%118.77M
81.27%104.76M
86.65%87.17M
-20.70%75.00M
193.50%71.53M
243.08%57.79M
429.49%46.70M
--94.58M
--24.37M
--16.85M
--8.82M
----
----
Operating profit
59.15%-13.45M
-14.12%-51.14M
-12.63%-65.07M
41.55%-36.02M
28.79%-32.92M
40.94%-44.82M
15.89%-57.77M
-11.92%-61.63M
25.79%-46.23M
-28.61%-75.89M
-950.90%-68.69M
1.17%-55.07M
-46.75%-62.30M
-49.22%-59.00M
82.93%-6.54M
-70.87%-55.72M
-27.08%-42.45M
-28.18%-39.54M
-37.51%-38.29M
-17.53%-32.61M
Net Profit
72.73%-12.88M
-6.96%-51.31M
-8.63%-64.54M
61.88%-28.56M
26.89%-47.23M
39.54%-47.97M
13.08%-59.41M
24.06%-74.91M
-3.86%-64.60M
-18.13%-79.34M
-509.35%-68.36M
-61.09%-98.65M
-38.77%-62.20M
-62.10%-67.17M
71.69%-11.22M
-80.24%-61.24M
-28.50%-44.82M
-28.36%-41.44M
-35.45%-39.63M
-16.50%-33.98M
Balance Sheet
Current assets
28.18%724.64M
22.35%656.57M
23.57%611.21M
21.42%588.99M
18.00%565.34M
15.89%536.62M
7.41%494.63M
-3.81%485.06M
-6.38%479.11M
-10.90%463.03M
51.25%460.49M
105.28%504.26M
102.77%511.76M
399.81%519.69M
250.63%304.45M
183.92%245.64M
119.42%252.38M
-26.60%103.98M
-47.39%86.83M
-52.99%86.52M
Total current liabilities
41.47%509.72M
34.59%460.45M
80.07%439.21M
64.64%378.84M
83.65%360.29M
83.36%342.10M
69.33%243.91M
65.72%230.10M
71.10%196.19M
62.27%186.57M
43.11%144.05M
43.80%138.85M
90.21%114.66M
170.08%114.97M
309.99%100.65M
318.64%96.56M
143.99%60.28M
86.19%42.57M
13.22%24.55M
-1.59%23.07M
Total assets
23.54%826.77M
19.02%761.45M
19.60%713.61M
21.34%689.80M
19.20%669.25M
16.70%639.78M
9.33%596.67M
-3.36%568.50M
-6.56%561.46M
-10.37%548.23M
40.23%545.73M
77.46%588.24M
77.27%600.86M
238.75%611.64M
339.45%389.18M
277.60%331.48M
190.71%338.96M
26.03%180.56M
-46.94%88.56M
-52.84%87.79M
Total liabilities
21.13%721.34M
19.66%678.14M
21.26%659.02M
17.60%601.51M
27.10%595.52M
27.24%566.71M
35.29%543.47M
28.75%511.48M
41.41%468.56M
33.81%445.37M
44.82%401.69M
79.01%397.26M
82.46%331.35M
101.28%332.83M
275.52%277.37M
207.56%221.92M
145.80%181.60M
130.22%165.36M
4.60%73.86M
-0.26%72.15M
Total equity
43.01%105.43M
14.00%83.30M
2.60%54.59M
54.86%88.30M
-20.64%73.73M
-28.95%73.08M
-63.06%53.20M
-70.15%57.02M
-65.53%92.90M
-63.11%102.85M
28.82%144.04M
74.32%190.98M
71.27%269.51M
1734.30%278.80M
660.73%111.81M
600.92%109.56M
268.37%157.36M
-78.72%15.20M
-84.74%14.70M
-86.26%15.63M
Cash Flow Statement
Net operating income
-1005.26%-9.47M
-1.63%-32.95M
52.28%-20.70M
28.81%-18.65M
105.61%1.05M
-7.68%-32.42M
18.88%-43.38M
13.70%-26.20M
65.21%-18.63M
45.60%-30.11M
-818.52%-53.47M
-10.15%-30.36M
-135.29%-53.55M
-65.04%-55.35M
82.17%-5.82M
4.43%-27.56M
15.01%-22.76M
-32.07%-33.54M
-19.98%-32.65M
-40.32%-28.84M
Net investment
-239.66%-197.00K
-3361.54%-450.00K
64.20%-121.00K
-136.67%-71.00K
35.56%-58.00K
75.00%-13.00K
-244.90%-338.00K
-328.57%-30.00K
75.74%-90.00K
60.90%-52.00K
-38.03%-98.00K
96.13%-7.00K
-461.64%-371.00K
99.75%-133.00K
66.78%-71.00K
---180.86K
74.46%-66.06K
-281944.07%-53.24M
-612.57%-213.74K
100.00%0.00
Net financing
-82.72%3.67M
39.38%48.15M
-89.77%2.99M
15.03%16.39M
-30.05%21.27M
140.24%34.54M
2565.88%29.27M
712300.00%14.24M
-8.89%30.41M
-94.16%14.38M
-102.30%-1.19M
-100.19%-2.00K
-81.14%33.37M
226.09%246.08M
65.80%51.56M
54.36%1.07M
40236.54%176.95M
3728.01%75.46M
287.36%31.10M
-66.96%690.48K

Revenue

By Business

Period:
No Data

By Region

Period:
No Data

FAQs

What is the total revenue of Axsome Therapeutics Inc?

According to Axsome Therapeutics Inc's FY2025 earnings report, its total revenue reached 638.50M, with a year-on-year change of 385.69M.

What are the current assets of Axsome Therapeutics Inc?

According to Axsome Therapeutics Inc's FY2025 earnings report, its current assets were 588.99M, with a year-on-year change of 21.42.

What are the total assets of Axsome Therapeutics Inc?

According to Axsome Therapeutics Inc's FY2025 earnings report, its total assets of Axsome Therapeutics Inc were 689.80M, with a year-on-year change of 21.34.

What are the total liabilities of Axsome Therapeutics Inc?

According to Axsome Therapeutics Inc's FY2025 earnings report, its total liabilities of Axsome Therapeutics Inc were 601.51M, with a year-on-year change of 17.60.

What is the total equity of Axsome Therapeutics Inc?

According to Axsome Therapeutics Inc's FY2025 earnings report, its total equity of Axsome Therapeutics Inc was 88.30M, with a year-on-year change of 54.86.

What is the net operating income of Axsome Therapeutics Inc?

According to Axsome Therapeutics Inc's FY2025 earnings report, its net operating income of Axsome Therapeutics Inc was -171.53M, with a year-on-year change of 32.05.

What is the net investment of Axsome Therapeutics Inc?

According to Axsome Therapeutics Inc's FY2025 earnings report, its net investment of Axsome Therapeutics Inc was -480.00K, with a year-on-year change of -77.78.

What is the net financing of Axsome Therapeutics Inc?

According to Axsome Therapeutics Inc's FY2025 earnings report, its net financing of Axsome Therapeutics Inc was 101.47M, with a year-on-year change of 75.42.

What is the Earnings Per Share (EPS) of Axsome Therapeutics Inc?

According to Axsome Therapeutics Inc's FY2025 earnings report, its Earnings Per Share (EPS) was -3.68, with a year-on-year change of 38.57.

What is the net income of Axsome Therapeutics Inc?

According to Axsome Therapeutics Inc's FY2025 earnings report, its net income was -183.17M, with a year-on-year change of 36.22.

What is the net margin of Axsome Therapeutics Inc?

According to Axsome Therapeutics Inc's FY2025 earnings report, its net profit margin was -28.69, with a year-on-year change of 61.48.

What is the gross margin of Axsome Therapeutics Inc?

According to Axsome Therapeutics Inc's FY2025 earnings report, its gross margin was 91.57, with a year-on-year change of 2.07.

What is the debt-to-asset ratio of Axsome Therapeutics Inc?

According to Axsome Therapeutics Inc's FY2025 earnings report, its debt-to-asset ratio was 28.20, with a year-on-year change of -13.39.

What is the Return on Equity (ROE) of Axsome Therapeutics Inc?

According to Axsome Therapeutics Inc's FY2025 earnings report, its Return on Equity (ROE) was -252.11, with a year-on-year change of -8.84.

What is the Return on Assets (ROA) of Axsome Therapeutics Inc?

According to Axsome Therapeutics Inc's FY2025 earnings report, its Return on Assets (ROA) was -29.11, with a year-on-year change of 41.37.

What is the operating profit of Axsome Therapeutics Inc?

According to Axsome Therapeutics Inc's FY2025 earnings report, its operating profit was -171.53M, with a year-on-year change of 32.05.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.
General Terms of Use
Privacy Policy
Cookie Policy